Amedisys, Inc. (NASDAQ: AMED) reported financial results for the three and six-month periods ended June 30, 2025. In the three-month period, net service revenue increased to $621.9 million, with a net income attributable to Amedisys, Inc. of $28.1 million. Adjusted EBITDA was $80.8 million. For the six-month period, net service revenue reached $1,216.6 million, with a net income of $89.1 million.

Adjusted net income attributable to Amedisys, Inc. for the three-month period was $51.4 million, with adjusted net income per diluted share of $1.54. For the six-month period, adjusted net income was $93.0 million, with adjusted net income per diluted share of $2.80. Amedisys will not conduct a quarterly earnings call due to the pending merger with UnitedHealth Group Incorporated.

Certain items impacting the financial results included merger-related expenses and impairment charges. Adjusted EBITDA, adjusted net income attributable to Amedisys, Inc., and adjusted net income per diluted share should not be considered as an alternative to, or more meaningful than, income before income taxes or other measures calculated in accordance with GAAP. The non-GAAP financial measures may not be comparable to measures reported by other companies.

Read more at GlobeNewswire: Amedisys Reports Second Quarter 2025 Financial Results